8/7/2019 epistaxis uj
1/50
EPISTAXISEPISTAXIS
SPR TeachingSPR Teaching
Y RamakrishnanY Ramakrishnan
20 Oct 2010
8/7/2019 epistaxis uj
2/50
OVERVIEWOVERVIEW
AnatomyAnatomy
PathophysiologyPathophysiology
ManagementManagement
Difficult casesDifficult cases
1. Juvenile Angiofibroma1. Juvenile Angiofibroma2. Osler Weber Rendu2. Osler Weber Rendu
8/7/2019 epistaxis uj
3/50
INTRODUCTIONINTRODUCTION
CommonCommon
Most of the time, bleeding is selfMost of the time, bleeding is self--limited, but can often be serious and lifelimited, but can often be serious and life--threatening.threatening.
AetiologyAetiology1. Local1. Local
2. Systemic2. Systemic
8/7/2019 epistaxis uj
4/50
Common causesCommon causes
LOCALLOCAL Nasal trauma (nose picking)Nasal trauma (nose picking)
Atrophic rhinitisAtrophic rhinitis
Bleeding polyp of the septum orBleeding polyp of the septum orlateral nasal wall (inverted papilloma)lateral nasal wall (inverted papilloma)
Neoplasms of the nose or sinusesNeoplasms of the nose or sinuses
Vascular malformation eg JAFVascular malformation eg JAF
SYSTEMIC (VASCULAR)SYSTEMIC (VASCULAR) HypertensionHypertension
CoagulopathyCoagulopathy--platelets, clotting (drugs,platelets, clotting (drugs,disease)disease)
OslerOsler--WeberWeber--Rendu SyndromeRendu Syndrome
8/7/2019 epistaxis uj
5/50
Nasal Septal Blood SupplyNasal Septal Blood Supply
ExternalCarotid Artery
-Sphenopalatine artery-Greater palatine artery
-Ascending pharyngeal artery
-Posterior nasal artery
-Superior Labial artery
InternalCarotid Artery
-Anterior Ethmoid artery
-Posterior Ethmoid artery
8/7/2019 epistaxis uj
6/50
Source ofbleedingSource ofbleeding
ANTERIOR vs POSTERIOR
1.1. Anterior (Kiesselbach plexus): younger, usually septal vs. anterior ethmoid,Anterior (Kiesselbach plexus): younger, usually septal vs. anterior ethmoid,most common (>90%), typically less severemost common (>90%), typically less severe
1.1. Posterior (Woodruffs plexus): older population, usually SPA, more seriousPosterior (Woodruffs plexus): older population, usually SPA, more serious
8/7/2019 epistaxis uj
7/50
Initial ManagementInitial Management
ABCsABCs
Medical history/MedicationsMedical history/Medications
Vital signsVital signs
Physical examPhysical exam
Anterior rhinoscopyAnterior rhinoscopy
Rigid endoscope (3 pass)Rigid endoscope (3 pass)
BloodsBloods
Radiologic studiesRadiologic studies EUA noseEUA nose
8/7/2019 epistaxis uj
8/50
Treatment optionsTreatment options
Control of hypertensionControl of hypertension
Correction of coagulopathies/thrombocytopeniaCorrection of coagulopathies/thrombocytopenia
FFP or whole blood/reversal of anticoagulant/plateletsFFP or whole blood/reversal of anticoagulant/platelets
Cautery (AgNo3 vs. electrocautery)Cautery (AgNo3 vs. electrocautery) Nasal packingNasal packing anterior (merocel, rapidrhino)/posterior (Foley, Storz Epistaxisanterior (merocel, rapidrhino)/posterior (Foley, Storz Epistaxis
Catheter, Xomed Treace Nasal Post Pac)Catheter, Xomed Treace Nasal Post Pac)
Transexamic acidTransexamic acid
Floseal (collagen + topical bovine thrombin)Floseal (collagen + topical bovine thrombin)
Greater palatine foramen blockGreater palatine foramen block
SurgerySurgery arterial ligation (see later)arterial ligation (see later)
-- septodermoplastyseptodermoplasty
EmbolisationEmbolisation
8/7/2019 epistaxis uj
9/50
Traditional Posterior PackTraditional Posterior Pack
8/7/2019 epistaxis uj
10/50
Greater Palatine Foramen BlockGreater Palatine Foramen Block
Pterygopalatine injection of 2ml 2%lidocaine/1:80 000 Adr via greater palatinecanal
Mechanism of action is volumecompression/vasospasm of IMA inpterygopalatine fossa
Landmark greater palatine canal =1/2 waybetween 2nd molar tooth and midline palate
Do not insert needle more than 25mm(orbit, intracranial)
C
an help minimise bleeding during SPAligation
8/7/2019 epistaxis uj
11/50
Surgical treatment
Sphenopalatine artery ligationSphenopalatine artery ligation
Maxillary artery ligationMaxillary artery ligation--Transmaxillary IMA ligationTransmaxillary IMA ligation
--Intraoral IMA ligationIntraoral IMA ligation
Anterior Ethmoidal ligationAnterior Ethmoidal ligation
External carotid artery ligationExternal carotid artery ligation Septodermoplasty/Laser ablationSeptodermoplasty/Laser ablation
GENERAL PRINCIPLE:GENERAL PRINCIPLE:
PROXIMAL LIGATION =GREATER FAILURE RATE (ANASTOMOSIS)PROXIMAL LIGATION =GREATER FAILURE RATE (ANASTOMOSIS)
8/7/2019 epistaxis uj
12/50
SPA ligationSPA ligation
8/7/2019 epistaxis uj
13/50
Sphenopalatine artery ligationSphenopalatine artery ligation
8/7/2019 epistaxis uj
14/50
Sphenopalatine artery ligationSphenopalatine artery ligation
8/7/2019 epistaxis uj
15/50
SPASPA clip or diathermy?clip or diathermy?
A retrospective chart review of patients undergoing SPA surgery between January 1995A retrospective chart review of patients undergoing SPA surgery between January 1995and 2005 (CharingCross, London)and 2005 (CharingCross, London)
n=67 n =13 bilateral procedures, n=6 concomitant anterior ethmoid artery occlusion,n=67 n =13 bilateral procedures, n=6 concomitant anterior ethmoid artery occlusion,n=12 concomitant septoplasty.n=12 concomitant septoplasty.
n=8 patients significant early ren=8 patients significant early re--bleeding.bleeding.
C
onclusionC
onclusionPlatelet levels on admission and not using diathermy to occlude the sphenopalatinePlatelet levels on admission and not using diathermy to occlude the sphenopalatineartery were independent risk factors for rebleeding (P values .03, and .02, respectively)artery were independent risk factors for rebleeding (P values .03, and .02, respectively)
Not using diathermy was also an independent risk factor for late operative failure onNot using diathermy was also an independent risk factor for late operative failure onCox regression, reducing the mean reCox regression, reducing the mean re--interventionintervention--free interval from 94 +/free interval from 94 +/-- 7 to 327 to 32+/+/-- 7 months (P < .007; hazard ratio 6.4; 95% confidence interval 1.77 months (P < .007; hazard ratio 6.4; 95% confidence interval 1.7--24.9).24.9).
Laryngoscope. 2007 Aug;117(8):1452Laryngoscope. 2007 Aug;117(8):1452--6.6.
Outcome ofendoscopic sphenopalatine artery occlusion for intractable epistaxis: a 10Outcome ofendoscopic sphenopalatine artery occlusion for intractable epistaxis: a 10--yearyear
experience.experience. Nouraei SANouraei SA,, Maani TMaani T,, HajioffDHajioffD, Saleh HA, Mackay IS., Saleh HA, Mackay IS.
8/7/2019 epistaxis uj
16/50
Maxillary artery ligationMaxillary artery ligation
8/7/2019 epistaxis uj
17/50
Anterior ethmoid artery ligationAnterior ethmoid artery ligation
Usually postUsually post--traumatictraumatic
Lynch incisionLynch incisionFrontoFronto--ethmoid suture lineethmoid suture line
24 (AEA)24 (AEA)--12(PEA)12(PEA)--6 (ON)6 (ON)
8/7/2019 epistaxis uj
18/50
ECA ligationECA ligation
Not as effectiveNot as effective
Neck incisionNeck incision
ECA= branches, ICA =no branchesECA= branches, ICA =no branches
Separate XII, XI and X nerves, beware sympatheticsSeparate XII, XI and X nerves, beware sympathetics
8/7/2019 epistaxis uj
19/50
Angiography/EmbolisationAngiography/Embolisation
First presented as an alternative to surgery by Sokoloff et al in 1974 and consisted ofparticle embolization of the ipsilateral IMA.
Later refined by Lasjaunias stressing the need for a standardized angiographic andtherapeutic approach.
Indications
1. Poor surgical candidates2. Refractory epistaxis following surgery
3. Preoperative Juvenille angiofibroma
Success rates variable
Complications
1. stroke/blindness - when embolic material inadvertently enters the ICA or
OphA through anastomosis with ECA.
2. facial necrosis/numbness
8/7/2019 epistaxis uj
20/50
8/7/2019 epistaxis uj
21/50
8/7/2019 epistaxis uj
22/50
HEREDITARY HAEMORRHAGICHEREDITARY HAEMORRHAGIC
TELANGECTASIA (HHT) orTELANGECTASIA (HHT) or OslerOsler--WeberWeber--RenduRendu
Initially described as a familial disease with abnormal vascular structures causing bleedingInitially described as a familial disease with abnormal vascular structures causing bleeding
from the nose and GI tractfrom the nose and GI tract
18961896 -- Henri Rendu describes the first classic caseHenri Rendu describes the first classic case
19011901 -- Sir William Osler describes an inherited disease of inadequate vesselsSir William Osler describes an inherited disease of inadequate vessels
First to suspect liver involvementFirst to suspect liver involvement
19071907 -- Frederick Weber publishes extensively on the subjectFrederick Weber publishes extensively on the subject
8/7/2019 epistaxis uj
23/50
HHTHHT
Prevalence is 1Prevalence is 1--2 cases per 100,000 population2 cases per 100,000 population
Autosomal dominantAutosomal dominant -- mutations in Transferring Growth Factor (TGF)mutations in Transferring Growth Factor (TGF)--beta signalingbeta signaling
Endoglin and ALKEndoglin and ALK--1 (TGF1 (TGF--B) receptorsB) receptors
PresentPresent telangectasiatelangectasia
-- recurrent epistaxis (puberty/adulthood)recurrent epistaxis (puberty/adulthood)
-- internal lesions (GI bleeds,pulmonary AVM, liver, cerebral, spinal)internal lesions (GI bleeds,pulmonary AVM, liver, cerebral, spinal)
--Family historyFamily history
DxDx clinical (Curacao criteria)clinical (Curacao criteria)
--skin biopsy (dilated capillaries + new vessel in dermis)skin biopsy (dilated capillaries + new vessel in dermis)
IxIx--CT/MRI (pulmonary, CNS, liver AVMs)CT/MRI (pulmonary, CNS, liver AVMs)
8/7/2019 epistaxis uj
24/50
PathophysiologyPathophysiology
The end result is that postThe end result is that post--capillary venules enlarge and connect to enlargingcapillary venules enlarge and connect to enlargingarterioles, thus forming direct arteriolararterioles, thus forming direct arteriolar--venular connectionsvenular connections
8/7/2019 epistaxis uj
25/50
HHTHHT
Treatment optionsTreatment options
1.1. PreventionPrevention-- nasal saline/emollientnasal saline/emollient
2.2. Cautery/laserCautery/laser--KTP,Nd:YAG/surgicelKTP,Nd:YAG/surgicel
3.3. HormonalHormonal OestrogenOestrogen
4.4. SurgerySurgery septodermoplasty (replace nasal mucosa inc IT with SSG)septodermoplasty (replace nasal mucosa inc IT with SSG)
--Young procedure (close nasal cavity)Young procedure (close nasal cavity)
5.5. DXT/IMRTDXT/IMRT
6.6. Thalidomide (NEWThalidomide (NEW mouse model HHT)mouse model HHT)
8/7/2019 epistaxis uj
26/50
DXTDXT
8/7/2019 epistaxis uj
27/50
JUVENILE ANGIOFIBROMAJUVENILE ANGIOFIBROMA
Up to 0.05% of head and neck tumors
Occurring almost exclusively in male adolescents ? hormonal
Theories SPA/vidian origin
-incomplete regression 1st branchial arch artery (Schik et al 2009) origin
IMA/SPA, marker of early embryonic angiogenesis (Laminin 2)
Intracranial Extension between 10-20%
Surgery and DXT
Recurrence Rates as high as 50%
Regular surveillance
8/7/2019 epistaxis uj
28/50
Origin
Posterolateral nasal wall near sphenopalatine foramen
Medial growth
-Nasal cavity
- Nasopharynx
Lateral growth
- Pterygopalatine fossa
-Infratemporal fossa
Intracranial extension
a) PM fissure
posterior orbit
SOF
cavernoussinus (most common)
b) pterygoid process (vidian canal) sphenoid
(body + greater wing) foramen lacerum + ICA
8/7/2019 epistaxis uj
29/50
Histology
Myofibroblast is cell of origin
Fibrous connective tissue with abundant endothelium lined vascular spaces
Pseudocapsule of fibrous tissue
Blood vessels lack a complete muscular layer
8/7/2019 epistaxis uj
30/50
Diagnosis
History nasal obstruction, epistaxis, proptosis, visual loss, facial pain/numbness,intracranial
Physical Exam pink, non-ulcerated mass
Radiological study1. CT Scan
2. MRI
3. Angiogram
8/7/2019 epistaxis uj
31/50
Radiological Studies
CT Scan
-Excellent for bone detail
-Lesion enhances with contrast on CT
- Holman-Miller Sign -Characteristic anterior bowing of posterior maxillary wall MRI
-Soft tissue + intraacranial extension
- salt and paper = flow voids
Angiogram
-Evaluation of feeding blood vessels
8/7/2019 epistaxis uj
32/50
Radkowski Staging
Radkowski et al. Arch. Otolaryngology, 1996
LimitationLimitation not take into account origin from pterygomaxiallary fissurenot take into account origin from pterygomaxiallary fissure
8/7/2019 epistaxis uj
33/50
8/7/2019 epistaxis uj
34/50
Presurgical - antiandrogen
Options: DES, flutamideOptions: DES, flutamide
Premise: in vitro (JNA tumor fibroblasts), volume shrinkage to facilitate surgicalPremise: in vitro (JNA tumor fibroblasts), volume shrinkage to facilitate surgicalexcisionexcision
Limited studies (n=11, 2 studies)Limited studies (n=11, 2 studies)
Conflicting results with flutamide:Conflicting results with flutamide:
a) Gates et al 1992a) Gates et al 1992 44% reduction (n=4/5)44% reduction (n=4/5)b) Labra et al 2004b) Labra et al 2004 11.1% reduction (n=6) over 6/5211.1% reduction (n=6) over 6/52
Labra A, ChavollaLabra A, Chavolla--Magaa R, LopezMagaa R, Lopez--Ugalde A, AlanisUgalde A, Alanis--Calderon J, HuertaCalderon J, Huerta--Delgado A. Flutamide as a preoperativeDelgado A. Flutamide as a preoperativetreatment in juvenile angiofibroma (JA) with intracranial invasion: report of 7 cases. Otolaryngol Head Necktreatment in juvenile angiofibroma (JA) with intracranial invasion: report of 7 cases. Otolaryngol Head Neck
Surg. 2004Surg. 2004
Gates GA, Rice DH, Koopmann CF Jr, Schuller DE. FlutamideGates GA, Rice DH, Koopmann CF Jr, Schuller DE. Flutamide--induced regression of angiofibroma Laryngoscope.induced regression of angiofibroma Laryngoscope.
1992 Jun;102(6):6411992 Jun;102(6):641--44
8/7/2019 epistaxis uj
35/50
Preoperative Embolization
Advantage volume reduction to faciliate complete excision Concern - ? Higher recurrence (tumor shrinkage into inaccesible cancelous bone)
24 to 72 hours preoperatively
Gelfoam or polyvinyl alcohol foam-Gelfoam: resorbed in approximately 2 weeks-Polyvinyl alcohol: more permanent
Efficacy-Stage I patients reduced from 840cc to 275cc blood loss
Complications- Brain and ophthalmic artery embolization
-Facial nerve palsy-Skin and soft tissue necrosis
Liu L et al. Analysis of intra-operative bleeding and recurrence of juvenile nasopharyngeal angiofibromas.
Clin Otolaryngol. 2002
8/7/2019 epistaxis uj
36/50
Surgical Approaches
Principles1. Adequate surgical approach
2. Control vascular supply IMA main feeder (behind tumour)
3. Lateral to medial dissection controlled and improved exposure of medial tumor
attachments (base pterygoid process/vidian canal)
4. Attention to microscopic residual tumor/prevention recurrence drilling vidian
canal/base pterygoid plate (Lloyd et al sphenoid invasion main predictor of recurrence)
Options Endoscopic transnasal
Transpalatal
Denker approach
Facial translocation
Medial maxillectomy
Infratemporal fossa with or without craniotomy
Lloyd G, Howard D, Lund VJ, Savy L. Imaging for juvenile angiofibroma. J Laryngol Otol. 2000 Sep;114(9):727-30
8/7/2019 epistaxis uj
37/50
Choosing the Surgical Approach
Smaller tumors (IA, IB, IIA, IIB, IIC)-Transnasal endoscopic
-Transpalatal
-Transantral: lesions extending laterally up to pterygopalatine fossa
Larger tumors (IIIA, IIIB)-Lateral rhinotomy-Midfacial degloving
Extensive resection with higher morbidity
Limited resection with higher recurrence
NOTE Extremely limited IIIA and IIIB may be approached endoscopically
8/7/2019 epistaxis uj
38/50
ChangingTechnique
Retrospective chart review of surgical intervention- 30 patients
Marked shift towards endonasal procedures while tumor stages remained thesame
Endonasal approach contraindicated in Stage IV and some Stage III cases
May be used in conjunction with other approach in these cases
Mann et al. Laryngoscope. 2004.
8/7/2019 epistaxis uj
39/50
Surgical Technique
Pryor et al. Laryngoscope. 2005
n=6 endoscopicn=6 endoscopic
8/7/2019 epistaxis uj
40/50
Surveillance
Recurrence Rates 20-50%
Frequent physical examinations
CT Scan / MRI
8/7/2019 epistaxis uj
41/50
Endoscopic Transnasal
Preop embolisation
Middle turbinectomy may be performed for
improved exposure
Middle meatus antrostomy
Resection of posterior maxillary wall
IMA/Sphenopalatine artery ligation
Tumor resection from pterygopalatine fossa
8/7/2019 epistaxis uj
42/50
Midface Degloving with Maxillary
Osteotomies
8/7/2019 epistaxis uj
43/50
External Beam Radiation
Retrospective review of efficacy of radiation as primary treatment modality for JNA
27 patients received 3000-5500 cGy
Recurrence rate of 15% 2-5 years post-treatment
External beam radiation is effective mode of treatment of advanced JNA
Lee JT et al. Laryngoscope. 2002
8/7/2019 epistaxis uj
44/50
External Beam Radiation
Long-term sequelae of concern
-panhypopituitarism (growth retardation), orbital complications (cataracts, posteriorcapsule opacification, optic atrophy), temporal lobe necrosis, malignant tumors
-reduced with IMRT?
Retrospective review reported 2 cases out of 55 patients developing secondarymalignancies
- Thyroid carcinoma 13 years after receiving 3500cGy
-Basal cell carcinoma of skin 14 years after receiving 3500cGy initially, then 3000cGyfor recurrence
Cummings et al. Laryngoscope 1984
8/7/2019 epistaxis uj
45/50
Conclusions
Rare, benign, vascular tumor found almost exclusively in young males
Surgery is the gold standard with a trend towards endoscopic approaches
Frequent follow-up after treatment is necessary
8/7/2019 epistaxis uj
46/50
QUESTIONS?QUESTIONS?
8/7/2019 epistaxis uj
47/50
AbstractsAbstracts
Clin Otolaryngol Allied Sci. 2002 Dec;27(6):536Clin Otolaryngol Allied Sci. 2002 Dec;27(6):536--40.40. Analysis of intraAnalysis of intra--operative bleeding and recurrence of juvenile nasopharyngealoperative bleeding and recurrence of juvenile nasopharyngeal
angiofibromas.angiofibromas. Liu LLiu L,,Wang RWang R,, Huang DHuang D,, Han DHan D,, Ferguson EJFerguson EJ,, Shi HShi H,,Yang WYang W..
Department of OtolaryngologyDepartment of Otolaryngology--Head and Neck Surgery, Chinese PLA GeneralHead and Neck Surgery, Chinese PLA GeneralHospital, Beijing, China. [email protected], Beijing, China. [email protected]
AbstractAbstract The purpose of this study is to present our experience with 34 patients diagnosed withThe purpose of this study is to present our experience with 34 patients diagnosed with
juvenile nasopharyngeal angiofibromas and treated in the Chinese PLA Generaljuvenile nasopharyngeal angiofibromas and treated in the Chinese PLA GeneralHospital between 1986 and 1999, and to examine the factors influencing intraHospital between 1986 and 1999, and to examine the factors influencing intra--operative bleeding and tumour recurrence. The age of the patient, the duration ofoperative bleeding and tumour recurrence. The age of the patient, the duration ofsymptoms and tumour stage were related to the amount of intrasymptoms and tumour stage were related to the amount of intra--operative bleeding.operative bleeding.The tumours were totally resected in 30 patients and recurred in five patients (16.7%),The tumours were totally resected in 30 patients and recurred in five patients (16.7%),
with a mean followwith a mean follow--up time of 77 months. The mean time to tumour recurrence afterup time of 77 months. The mean time to tumour recurrence afteroperation was 3.2 months (1operation was 3.2 months (1--6 months). The incidence of recurrence had no6 months). The incidence of recurrence had nocorrelation with the age of the patient, duration of symptoms, pericorrelation with the age of the patient, duration of symptoms, peri--operative treatmentoperative treatmentor surgical approaches (P > 0.05); but strongly correlated with tumour stage (P 0.05); but strongly correlated with tumour stage (P or = 30 patients), shorter lengthloss (225 vs. 1,250 mL), a lower occurrence of complications (1 patient vs. > or = 30 patients), shorter lengthof hospital stay (2 vs. 5 days), and lower rate of recurrence (0% vs. 24%).of hospital stay (2 vs. 5 days), and lower rate of recurrence (0% vs. 24%).
CONCLUSION: Endoscopic removal of JNA tumor appears to be safe and effective. Recurrence was notCONCLUSION: Endoscopic removal of JNA tumor appears to be safe and effective. Recurrence was notappreciably affected by approach.appreciably affected by approach.
8/7/2019 epistaxis uj
50/50
Herman 1999Herman 1999
Laryngoscope. 1999 Jan;109(1):140Laryngoscope. 1999 Jan;109(1):140--7.7.
LongLong--term followterm follow--up of juvenile nasopharyngeal angiofibromas: analysis ofrecurrences.up of juvenile nasopharyngeal angiofibromas: analysis of recurrences.
Herman PHerman P,, Lot GLot G,, Chapot RChapot R,, Salvan DSalvan D,, Huy PTHuy PT..
Department of Ear, Nose, and Throat Medicine, Hpital Lariboisire, Paris, France.Department of Ear, Nose, and Throat Medicine, Hpital Lariboisire, Paris, France.
AbstractAbstract
OBJECTIVES: Juvenile nasopharyngeal angiofibroma often recurs if the tumor is large. This report is a longOBJECTIVES: Juvenile nasopharyngeal angiofibroma often recurs if the tumor is large. This report is a long--term followterm follow--up of these cases. It establishes the prognostic values of tumor extensions, analyzes the anatomicup of these cases. It establishes the prognostic values of tumor extensions, analyzes the anatomic
factors involved in recurrences, describes the spontaneous evolution of remnants based on a radiographicfactors involved in recurrences, describes the spontaneous evolution of remnants based on a radiographicfollowfollow--up, and evaluates the pertinence of complex combined surgical approaches for invasive tumors and theup, and evaluates the pertinence of complex combined surgical approaches for invasive tumors and thevalue of complementary endoscopy.value of complementary endoscopy.
STUDY DESIGN: Retrospective review of 44 cases treated between 1985 and 1996.STUDY DESIGN: Retrospective review of 44 cases treated between 1985 and 1996.
METHODS: Statistical analysis of the correlation between recurrence and tumor extension as evaluated byMETHODS: Statistical analysis of the correlation between recurrence and tumor extension as evaluated bysystematic analysis of 18 putative tumor extensions on preoperative computed tomography scans.systematic analysis of 18 putative tumor extensions on preoperative computed tomography scans.
RESULTS: Invasion of the skull base affected twoRESULTS: Invasion of the skull base affected two--thirds of the patients, and the rate of recurrence was 27.5%.thirds of the patients, and the rate of recurrence was 27.5%.Extensions to the infratemporal fossa, sphenoid sinus, base of pterygoids and clivus, the cavernous sinusExtensions to the infratemporal fossa, sphenoid sinus, base of pterygoids and clivus, the cavernous sinus(medial), foramen lacerum, and anterior fossa were correlated with more frequent recurrence. Long(medial), foramen lacerum, and anterior fossa were correlated with more frequent recurrence. Long--termterm
radiographic followradiographic follow--up revealed putative residual disease in nine asymptomatic patients: these remnantsup revealed putative residual disease in nine asymptomatic patients: these remnantsgradually involuted.gradually involuted.
CONCLUSIONS: The data in the current study emphasize the prognostic value of skull base invasion and theCONCLUSIONS: The data in the current study emphasize the prognostic value of skull base invasion and thedifficulty of complete resection of extended lesions. Tumor remnants detected in symptomdifficulty of complete resection of extended lesions. Tumor remnants detected in symptom--free patients shouldfree patients shouldbe kept under surveillance by repeated computed tomography scan, since involution may occur. Recurrentbe kept under surveillance by repeated computed tomography scan, since involution may occur. Recurrentsymptoms may be treated by radiotherapy (30 Gy) rather than by extended combined procedures. Endoscopicsymptoms may be treated by radiotherapy (30 Gy) rather than by extended combined procedures. Endoscopicsurgery should be combined with surgery for better control of skull base extensions.surgery should be combined with surgery for better control of skull base extensions.